期刊档案

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS

— · ISSN 0743-4863 · 医学-药学

数据可追溯 · letpub-v6 · 更新于 2026-08-25
影响指标2.4
h-index69
平均审稿速度网友分享经验:>12周,或约稿
平均录用比例网友分享经验:较易

期刊简介

研究范围与定位

Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields.Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.

结构化分区

学科分区明细

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值。

《新锐期刊分区表》( 2026年3月发布)

2026-03 · 2 个学科记录

Top:否综述:N/A
类别学科分区
大类医学4区
小类药学PHARMACOLOGY & PHARMACY4区

期刊分区表( 2025年3月升级版)

2025-03 · 2 个学科记录

Top:否综述:是
类别学科分区
大类医学4区
小类药学PHARMACOLOGY & PHARMACY4区

期刊分区表( 2023年12月旧的升级版)

2023-12 · 2 个学科记录

Top:否综述:是
类别学科分区
大类医学4区
小类药学PHARMACOLOGY & PHARMACY4区

期刊档案

出版与身份

期刊ISSN
0743-4863
E-ISSN
2162-660X
是否OA开放访问
No
通讯方式
BEGELL HOUSE INC, 50 CROSS HIGHWAY, REDDING, USA, CT, 06896
出版商
Begell House Inc.
出版国家或地区
UNITED STATES
出版语言
English
出版周期
Bimonthly
出版年份
1984

期刊档案

研究范围

期刊简介
Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields.Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.
涉及的研究方向
医学-药学

期刊档案

指标与活跃度

2025-2026最新IF(数据来源于网友提供)
注册或登录后,查看IF
实时影响因子
截止2026年5月06日:2.4
2025-2026自引率
16.0%点击查看自引率趋势图
五年IF(数据来源于网友提供)
2.699数据由网友[crazy萤火虫54]收集提供
h-index
69
CiteScore ( 2026年6月最新版)
CiteScoreSJRSNIPCiteScore排名6.000.4690.617学科分区排名百分位大类:Pharmacology, Toxicology and Pharmaceutics小类:Pharmaceutical ScienceQ259 / 191 69% 大类:Pharmacology, Toxicology and Pharmaceutics小类:PharmacologyQ2104 / 328 68%
年文章数
18点击查看年文章数趋势图
Gold OA文章占比
0.00%
研究类文章占比:文章 ÷(文章 + 综述)
0.00%

期刊档案

分区、收录与风险

WOS期刊JCR分区 ( 2025-2026年最新版)
注册或登录后,查看WOS分区等级
期刊分区表预警名单
2026年03月发布的新锐学术版:不在预警名单中2025年03月发布的2025版:不在预警名单中2024年02月发布的2024版:不在预警名单中2023年01月发布的2023版:不在预警名单中2021年12月发布的2021版:不在预警名单中2020年12月发布的2020版:不在预警名单中
SCI期刊收录coverage
Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)Scopus (CiteScore)
PubMed Central (PMC)链接
访问官方页面 ↗

期刊档案

投稿与评审

期刊官方网站
访问官方页面 ↗
期刊投稿网址
访问官方页面 ↗
平均审稿速度
网友分享经验:>12周,或约稿
平均录用比例
网友分享经验:较易

来源与统计口径

来源:LetPub 原始详情页 ↗。投稿经验仅展示聚合统计,不公开第三方正文或用户标识。当前聚合样本:暂无。